CONTRAVE Earns Top Recommendation in New Obesity Treatment Guidelines Currax Pharmaceuticals celebrates CONTRAVE's inclusion in the latest obesity treatment guidelines, underscoring its effectiveness for weight management.

CONTRAVE Earns Top Recommendation in New Obesity Treatment Guidelines #United_States #Brentwood #Currax #CONTRAVE #Obesity_Guidelines

Currax Pharmaceuticals Unveils Promising Data on CONTRAVE®'s Effectiveness During ObesityWeek® Currax Pharmaceuticals showcases promising data on CONTRAVE®'s ability to control cravings during ObesityWeek®, revealing significant outcomes for specific populations.

Currax Pharmaceuticals Unveils Promising Data on CONTRAVE®'s Effectiveness During ObesityWeek® #USA #Atlanta #CONTRAVE #Currax_Pharmaceuticals #ObesityWeek

Currax Pharmaceuticals to Showcase BREAKTHROUGH Research at ObesityWeek® 2025 on CONTRAVE® and Weight Management Currax Pharmaceuticals will present significant research on CONTRAVE® at ObesityWeek 2025, revealing its impact on craving control and weight management.

Currax Pharmaceuticals to Showcase BREAKTHROUGH Research at ObesityWeek® 2025 on CONTRAVE® and Weight Management #United_States #Atlanta #CONTRAVE #Currax_Pharmaceuticals #ObesityWeek

Currax Pharmaceuticals Offers CONTRAVE® Free for Federal Employees Amid Shutdown Crisis In response to the ongoing government shutdown, Currax Pharmaceuticals has announced it will provide its weight-loss medication, CONTRAVE®, at no cost to eligible federal employees and retirees.

Currax Pharmaceuticals Offers CONTRAVE® Free for Federal Employees Amid Shutdown Crisis #United_States #Brentwood #government_shutdown #CONTRAVE #Currax_Pharmaceuticals

Currax targets affordability with new Contrave cash-pay program As GLP-1 giants like Novo Nordisk and Eli Lilly go direct-to-consumer, Currax bets on oral therapy access.

As GLP-1 giants like Novo Nordisk and Eli Lilly go direct-to-consumer, Currax bets on oral therapy access. the company is launching cash-pay models to expand access to its oral weight loss therapy, Contrave.

#news #weightloss #obesity #WeightLossDrugs #Contrave #GLP1 #LillyDirect #NovoCare

Currax targets affordability with new Contrave cash-pay program As GLP-1 giants like Novo Nordisk and Eli Lilly go direct-to-consumer, Currax bets on oral therapy access.

As GLP-1 giants like Novo Nordisk and Eli Lilly go direct-to-consumer, Currax bets on oral therapy access. the company is launching cash-pay models to expand access to its oral weight loss therapy, Contrave.

#news #weightloss #obesity #WeightLossDrugs #Contrave #GLP1 #LillyDirect #NovoCare

Currax Enhances Accessibility of Contrave for Weight Management with GoodRx Initiative Currax Pharmaceuticals broadens access to its weight loss treatment Contrave® through GoodRx, providing affordable options to those with obesity.

Currax Enhances Accessibility of Contrave for Weight Management with GoodRx Initiative #USA #Brentwood #Currax #CONTRAVE #GoodRx

Saxenda savings tips Saxenda coupons can help you save about $600 per month. Learn how and access more ways to save.

“There are also a number of oral medications that are FDA approved for weight management,” says Jessica Cutler, MD, of The Maryland Bariatric Center at Mercy Medical Center in Baltimore. These include #Qsymia and #Contrave. #weightloss
www.singlecare.com/blog/how-to-...

Currax Pharmaceuticals Expands CONTRAVE Production with FDA Approval of New Facility Currax Pharmaceuticals has secured FDA approval for a second manufacturing site for their weight loss drug CONTRAVE, ensuring broader patient access and meeting the rising demand for obesity treatments.

Currax Pharmaceuticals Expands CONTRAVE Production with FDA Approval of New Facility #United_States #FDA_Approval #Brentwood #CONTRAVE #Currax_Pharmaceuticals

Currax Pharmaceuticals' New Study Confirms Safety of Weight Loss Drug CONTRAVE®/MYSIMBA® Currax Pharmaceuticals has published new evidence highlighting the cardiovascular safety of its weight loss medication CONTRAVE®/MYSIMBA®, reinforcing its efficacy in treating obesity.

Currax Pharmaceuticals' New Study Confirms Safety of Weight Loss Drug CONTRAVE®/MYSIMBA® #USA #Brentwood #Currax #CONTRAVE #MYSIMBA

Currax Pharmaceuticals Reaches Settlement Over Found Health Litigation Concerning Weight Loss Medications Currax Pharmaceuticals has settled its litigation against Found Health Inc. over improper marketing claims related to their weight loss medication, CONTRAVE.

Currax Pharmaceuticals Reaches Settlement Over Found Health Litigation Concerning Weight Loss Medications #United_States #Brentwood #Currax #CONTRAVE #Found_Health

Contrave Chronicles

#weightloss #contrave

Contrave Chronicles
#weightloss #contrave

Contrave Chronicles
#contrave #weightloss

Currax Pharmaceuticals Achieves Remarkable Financial Growth and Operational Milestones for 2024 Currax Pharmaceuticals has reported exceptional results in 2024, including over 50% revenue growth, strategic operational advancements, and a global expansion in demand for its products.

Currax Pharmaceuticals Achieves Remarkable Financial Growth and Operational Milestones for 2024 #United_States #Brentwood #CONTRAVE #Currax_Pharmaceuticals #MYSIMBA

Currax Launches Revolutionary Campaign to Combat Food Cravings with CONTRAVE® TV Ad Currax Pharmaceuticals has introduced its first TV advertisement for CONTRAVE® and launched the 'Cravings Don't Own Me' campaign, tackling food cravings in weight loss efforts.

Currax Launches Revolutionary Campaign to Combat Food Cravings with CONTRAVE® TV Ad #United_States #Brentwood #Currax #CONTRAVE #Food_Cravings